Vor Biopharma (VOR)

NASDAQ:VOR

VOR

Vor Biopharma

RESEARCH TOOLSreports

Want to see VOR full AI Analyst Report?

Vor Biopharma (VOR) Stock Forecast & Price Target

960 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VOR Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Vor

Biopharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VOR Stock 12 Month Forecast

Average Price Target

$33.80

▲(103.74% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $33.80 with a high forecast of $50.00 and a low forecast of $18.00. The average price target represents a 103.74% change from the last price of $16.59.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","15":"$15","27":"$27","39":"$39","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,15,27,39,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.85,16.630769230769232,19.411538461538463,22.192307692307693,24.973076923076924,27.753846153846155,30.534615384615385,33.315384615384616,36.09615384615385,38.87692307692308,41.65769230769231,44.43846153846154,47.21923076923077,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.85,15.384615384615383,16.91923076923077,18.45384615384615,19.988461538461536,21.52307692307692,23.057692307692307,24.592307692307692,26.126923076923074,27.661538461538456,29.19615384615384,30.730769230769226,32.26538461538461,{"y":33.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.85,14.169230769230769,14.488461538461538,14.807692307692307,15.126923076923077,15.446153846153846,15.765384615384615,16.084615384615383,16.403846153846153,16.723076923076924,17.04230769230769,17.361538461538462,17.68076923076923,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.22,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.79,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$33.80

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Martin Fan

Wedbush

$15→$18

Hold

8.50%

Upside

Reiterated

05/14/26

Vor Bio price target raised to $18 from $15 at WedbushVor Bio price target raised to $18 from $15 at Wedbush

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

05/13/26

Analysts Are Bullish on These Healthcare Stocks: Protara Therapeutics (TARA), Vor Biopharma (VOR)

Sadia Rahman

Wells Fargo

$30

Buy

80.83%

Upside

Reiterated

05/13/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (NASDAQ: STAA), Halozyme (NASDAQ: HALO) and Vor Biopharma (NASDAQ: VOR)

Swayampakula Ramakanth

H.C. Wainwright

$32→$31

Buy

86.86%

Upside

Reiterated

04/15/26

Vor Bio price target lowered to $31 from $32 at H.C. WainwrightVor Bio price target lowered to $31 from $32 at H.C. Wainwright

Stephen Willey

Stifel Nicolaus

$40

Buy

141.11%

Upside

Reiterated

04/08/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Vor Biopharma (NASDAQ: VOR) and Bristol-Myers Squibb (NYSE: BMY)

Farzin Haque

Jefferies

$50

Buy

201.39%

Upside

Initiated

03/29/26

Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating

Geoff Meacham

Citi

$50

Buy

201.39%

Upside

Reiterated

01/30/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jack Allen

Robert W. Baird

$64→$46

Buy

177.28%

Upside

Reiterated

12/23/25

Vor Bio price target lowered to $46 from $64 at BairdVor Bio price target lowered to $46 from $64 at Baird

Anupam Rama

J.P. Morgan

$43→$40

Buy

141.11%

Upside

Reiterated

12/18/25

Vor Bio price target lowered to $40 from $43 at JPMorganVor Bio price target lowered to $40 from $43 at JPMorgan

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Martin Fan

Wedbush

$15→$18

Hold

8.50%

Upside

Reiterated

05/14/26

Vor Bio price target raised to $18 from $15 at WedbushVor Bio price target raised to $18 from $15 at Wedbush

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

05/13/26

Analysts Are Bullish on These Healthcare Stocks: Protara Therapeutics (TARA), Vor Biopharma (VOR)

Sadia Rahman

Wells Fargo

$30

Buy

80.83%

Upside

Reiterated

05/13/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (NASDAQ: STAA), Halozyme (NASDAQ: HALO) and Vor Biopharma (NASDAQ: VOR)

Swayampakula Ramakanth

H.C. Wainwright

$32→$31

Buy

86.86%

Upside

Reiterated

04/15/26

Vor Bio price target lowered to $31 from $32 at H.C. WainwrightVor Bio price target lowered to $31 from $32 at H.C. Wainwright

Stephen Willey

Stifel Nicolaus

$40

Buy

141.11%

Upside

Reiterated

04/08/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Vor Biopharma (NASDAQ: VOR) and Bristol-Myers Squibb (NYSE: BMY)

Farzin Haque

Jefferies

$50

Buy

201.39%

Upside

Initiated

03/29/26

Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating

Geoff Meacham

Citi

$50

Buy

201.39%

Upside

Reiterated

01/30/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jack Allen

Robert W. Baird

$64→$46

Buy

177.28%

Upside

Reiterated

12/23/25

Vor Bio price target lowered to $46 from $64 at BairdVor Bio price target lowered to $46 from $64 at Baird

Anupam Rama

J.P. Morgan

$43→$40

Buy

141.11%

Upside

Reiterated

12/18/25

Vor Bio price target lowered to $40 from $43 at JPMorganVor Bio price target lowered to $40 from $43 at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vor Biopharma

3 Months

xxx

Success Rate

7/14 ratings generated profit

Average Return

-9.34%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -9.34% per trade.

1 Year

Stephen WilleyStifel Nicolaus

Success Rate

3/18 ratings generated profit

Average Return

-50.49%

Copying Stephen Willey's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -50.49% per trade.

2 Years

xxx

Success Rate

2/14 ratings generated profit

Average Return

-59.60%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 14.29% of your transactions generating a profit, with an average return of -59.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VOR Analyst Recommendation Trends

Rating

Jan 26

Feb 26

Mar 26

Apr 26

May 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VOR has received 9 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. VOR average Analyst price target in the past 3 months is 33.80.

Each month's total comprises the sum of three months' worth of ratings.

VOR Financial Forecast

VOR Earnings Forecast

The previous quarter’s earnings for VOR were -$5.11.

No data currently available

VOR Sales Forecast

The previous quarter’s earnings for VOR were $0.00.

VOR Stock Forecast FAQ

What is VOR’s average 12-month price target, according to analysts?

Based on analyst ratings, Vor Biopharma’s 12-month average price target is 33.80.

What is VOR’s upside potential, based on the analysts’ average price target?

Vor Biopharma has 103.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VOR a Buy, Sell or Hold?

Vor Biopharma has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Vor Biopharma’s price target?

The average price target for Vor Biopharma is 33.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $18.00. The average price target represents 103.74% Increase from the current price of $16.59.

What do analysts say about Vor Biopharma?

Vor Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of VOR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Vor Biopharma (VOR) Stock Forecast & Price Target

VOR Analyst Ratings

VOR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vor Biopharma

VOR Analyst Recommendation Trends

VOR Financial Forecast

VOR Earnings Forecast

VOR Sales Forecast

VOR Stock Forecast FAQ

Detailed List of Analyst Forecasts